Transporter-Independent Pharmacology and the Orphan PRV Playbook
Dr. Dereck Mush, MD, MBA
Egetis Therapeutics
Rare disease drug developer behind Emcitate (tiratricol) for MCT8 deficiency.
Egetis Therapeutics is known for rare disease drug developer behind Emcitate (tiratricol) for MCT8 deficiency. It is based in Stockholm, Sweden, is at the Public stage, and sits in our Pharma & Drug Discovery category.
What they do
Egetis Therapeutics develops treatments for rare diseases. On September 28, 2026 the FDA approved Emcitate (tiratricol), tablets for oral suspension, to treat peripheral thyrotoxicosis in adults and children with MCT8 deficiency (Allan-Herndon-Dudley syndrome). It is given once daily by mouth or feeding tube. The company expects US availability eight to ten weeks after approval.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Rare disease endocrinology
- Product type
- Therapeutic
- Stage
- Public
- Headquarters
- Stockholm, Sweden
- Region
- Europe
- Founded
- 2020
- Total funding
- Undisclosed
Also in Pharma & Drug Discovery
More in Pharma & Drug Discovery: Pharma & Drug Discovery startups/HealthTech startup database
Related on The Signal
Dr. Dereck Mush, MD, MBA
A CDMO partnership shows how gene therapy manufacturing is scaling for chronic disease
Dr. Dereck Mush, MD, MBA
The MCT8 Treatment Boundary: What Emcitate's Approval Changes and What It Leaves Open
Dr. Dereck Mush, MD, MBA
The Oral Endocrine Pivot: Inside Sling Therapeutics' $123M Bet on Linsitinib
Dr. Dereck Mush, MD, MBA